Download the white paper to learn more.
The increasing complexity and pace of drug development have revealed a critical gap in the genomic toolkit. In preclinical and translational research settings, teams must evaluate safety, efficacy, and mechanism of action across large multivariable studies, often within tight timelines and with limited biological material. Yet the tools traditionally used for gene expression analysis are increasingly misaligned with these demands, delaying data‑driven internal research go/no‑go decisions and slowing program progress.
Researchers need a technology that fills the gap between the low‑throughput verification of conventional plate‑based quantitative PCR (qPCR) and the high‑cost, discovery‑oriented scale of next‑generation sequencing.
This white paper explores the limitations of traditional technologies and presents case studies demonstrating the effectiveness of an alternative research approach, covering topics such as:
- Why modern drug development studies demand a new research approach
- How microfluidic qPCR technology addresses these demands
- Using microfluidic qPCR in research‑stage pharmacodynamic gene expression studies
- Enabling research biomarker exploration and target validation
- Profiling gene expression to study immunosuppression‑related pathways in research models
For Research Use Only. Not for use in diagnostic procedures.
All product and company names are trademarks™ or registered® trademarks of their respective holders. Use of them does not imply any affiliation with or endorsement by them. Third party trademarks do not indicate an endorsement of any Standard BioTools products or services.
Offered Free by: Standard Biotools
See All Resources from: Standard Biotools
